组蛋白H3K27去甲基化酶与肿瘤发生

组蛋白甲基化是一种重要的表观遗传学修饰,在基因表达调节方面发挥着重要的作用.组蛋白H3赖氨酸27三甲基化（H3K27me3）是一种抑制性组蛋白标记,可被去甲基化酶UTX和JMJD3催化而移去甲基.UTX和JMJD3通过激活HOX基因而参与细胞分化和多能细胞抑制过程.在多种肿瘤中检测到UTX和JMJD3突变或表达下降,同时多种基因启动子区H3K27me3含量增多.UTX和JMJD3均被看作肿瘤抑制基因,其中UTX调节了RB依赖的细胞命运控制,而JMJD3通过激活INK4b-ARF-INK4a位点而参与了癌基因诱导的衰老.组蛋白H3K27去甲基化酶与肿瘤发生的研究使我们对癌症发展过程有了更好的理解,同时也为癌症诊断和治疗提供了新靶点.     

PI3K/AKT信号通路调控Myogenin和MCK基因的表达

骨骼肌分化过程受多个信号通路调控, PI3K/AKT信号通路是其中最重要的信号转导通路之一。PI3K/AKT信号通路可以调控骨骼肌分化, 但在染色质水平上的调控机制还不是很清楚。文章以小鼠成肌细胞(C2C12)为研究材料, 采用免疫印迹、染色质免疫共沉淀(Chromatin immunoprecipitation, ChIP)、定量PCR (Q-PCR)的方法研究PI3K/AKT信号通路调控Myogenin和MCK基因的表达。研究发现, C2C12细胞分化过程中添加PI3K/AKT信号通路激活剂处理24 h, Myogenin和MCK蛋白表达水平显著升高, 组蛋白H3K27me3去甲基化酶UTX的表达也升高, H3K27me3在Myogenin基因启动子区和MCK基因启动子及增强子区的富集与对照组相比显著降低。用PI3K/AKT信号通路抑制剂处理, 结果相反。因此, PI3K/AKT信号通路可能通过调控组蛋白去甲基化酶UTX的表达活性改变靶基因的H3K27me3的富集进而调控骨骼肌分化。     

组蛋白去甲基化酶JMJD3研究进展

组蛋白甲基化状态是有不同类型的甲基转移酶和去甲基化酶来控制的。H3K27me2/3可以由多梳家族蛋白(如甲基转移酶EZH2)控制形成,其去甲基化后可以催化基因表达。目前共鉴定出JMJD3和UTX两种H3K27me3的去甲基化酶。大量研究发现,JMJD3可以促进细胞分化和衰老,参与调控肿瘤发生与发展。综述了JMJD3在胚胎发育及肿瘤发生、发展中的作用及其调节机制,并对其在肿瘤诊断和治疗方面的应用前景进行展望,旨为今后的研究工作奠定理论基础。     

组蛋白去甲基酶UTX在发育和疾病中的作用

UTX(ubiquitously transcribed tetratricopeptide repeat,X chromosome)是抑制性组蛋白H3K27me3的特异性去甲基化酶,和甲基转移酶PRC2共同调控H3K27me3。此外,UTX也是组蛋白H3K4甲基转移酶MLL3/MLL4的组成部分。UTX参与胚胎发育、HOX基因的表达和重编程等生命过程。在歌舞伎综合征中,UTX突变是关键的致病因素。同时,UTX作为肿瘤抑制因子参与多种实体肿瘤和血液肿瘤的产生。该文总结了UTX在正常发育和疾病发生中的作用及近期研究的重大突破,并结合我们的研究探讨了UTX对体细胞重编程的影响。     

组蛋白去甲基化酶JMJD1A

组蛋白翻译后修饰可影响特定基因的表达,从而在多个生理过程中发挥重要作用,是当前生命科学领域的研究热点之一。组蛋白去甲基化酶JMJD1A可催化一甲基化和二甲基化的H3K9(H3K9me1/2)去甲基化,通过解除组蛋白抑制效应而调节基因表达。JMJD1A拥有广泛的生物学功能,参与多种生物学过程包括核受体激活、精子生成、能量代谢、低氧调节和癌症发生等。本文就JMJD1A的特征及功能作一综述。     

组蛋白赖氨酸去甲基化酶在肿瘤中的作用

在肿瘤发生过程中,组蛋白赖氨酸去甲基化酶(LSD1)的表达失调是一个重要标志。LSD1能够于组蛋白H3的N端与H3K4me2/1和H3K9me2/1相互作用,并使其去甲基化,从而调控多种不同的生理过程。同时,LSD1表达水平变化还与多种基因如p53、DNMT1和EZH2等的表达水平相关联,在胚胎发育、细胞分化和肿瘤增殖转移过程中起重要作用。     

组蛋白去甲基化酶KDM5A调控H3K4me3参与神经管畸形发生的分子机制

神经管畸形(NTDs)的病因与防治是出生缺陷领域研究的重点,叶酸可以预防神经管畸形但其机制不明。本文借助低叶酸细胞模型和低叶酸NTDs小鼠模型通过染色质免疫共沉淀、Cut&Tag等技术,探讨了组蛋白去甲基化酶lysine demethylase 5A(KDM5A)及其调控的下游组蛋白H3K4me3修饰在叶酸缺乏导致的NTDs发生中的潜在分子机制。结果显示,低叶酸的细胞模型中,qRT-PCR、Western印迹结果显示,KDM5A分子表达明显下降(P<0.05)。作为组蛋白H3K4me3调控的上游关键酶,进一步通过染色质免疫共沉淀ChIP、ChIP-qPCR实验证实,叶酸缺乏下组蛋白H3K4me3在神经发育基因Axin2和Atoh1基因启动子区富集增加(P<0.05)。通过构建KDM5A基因敲除细胞模型,借助Cut&Tag试验证实,KDM5A基因敲除后H3K4me3主要富集在神经发育基因上。最后在低叶酸导致的NTDs小鼠模型的脑组织中,RT-qPCR、Western印迹以及ChIP-qPCR实验显示,E9.5 d的NTDs胎鼠脑组织中KDM5A表达下降(P&l...     

组蛋白去甲基化酶KDM3B结构、功能及其相关疾病研究进展

表观遗传学是研究在DNA序列不变的前提下,其他机制异常引起基因表达改变并可遗传的学科。组蛋白甲基化/去甲基化修饰是表观遗传学的重要调控机制之一,是甲基化酶和去甲基化酶动态相互作用的结果,其中H3K9的甲基化和去甲基化是近年来研究最深入的组蛋白修饰之一。组蛋白去甲基化酶KDM3B包含一个JmjC结构域,并具有固有的H3K9去甲基化活性,能够特异性去除H3K9me1/2甲基化修饰,调控基因转录、DNA损伤修复,参与细胞增殖、细胞凋亡、干细胞干性维持、肿瘤和遗传病发生发展等。该文就组蛋白去甲基化酶KDM3B的结构、作用机制、生物学功能及其成为一个临床研究和治疗的潜在药理学靶点的可能性作一综述。     

组蛋白去甲基化酶UTX与胚胎发育及疾病关系

组蛋白3赖氨酸27(histone 3 lysine 27, H3K27)去甲基化酶UTX(ubiquitously transcribed tetratricopeptide repeat on chromosome X, UTX)为X染色体上重复的转录三十四肽,是组蛋白3赖氨酸4(histone 3 lysine 4, H3K4)甲基转移酶复合物MLL2(mixed-lineage leukemia 2, MLL2)中的一员,可调节同源基因HOX(homeobox, HOX)和视网膜母细胞瘤基因RB(retinoblastoma, RB)转录谱系. UTX与BRG1-SWI/SNF重塑复合物(Brg1-containing ATPase-dependent Swi/Snf chromatin-remodeling complex, BRG1-SWI/SNF)相互作用促进染色质重塑. 因其在细胞的正确再编程、胚胎发育和组织特异性分化中扮演重要角色,UTX失活或缺失会导致癌症、胚胎发育缺陷等疾病的发生. 本文将对近年来UTX在胚胎发育及与疾病关系方面的研究进展做一综述.     

组蛋白去甲基化酶UTX的研究进展

UTX是一种含有多个TPR结构域和一个JmjC催化结构域的组蛋白修饰酶,主要负责去除H3K27位点的二/三甲基化。在分子机制上,UTX一方面可通过其去甲基化酶活性降低靶基因启动子或增强子上的H3K27me2/3水平,另一方面可与MLL3/4形成复合物调控增强子的H3K4甲基化水平,从而促进基因转录。此外,UTX还可以通过与组蛋白乙酰转移酶p300或去乙酰化酶HDAC1相互作用从而调控组蛋白乙酰化水平,进而影响基因转录。在生理病理方面,UTX主要参与生长发育、组织分化、免疫以及代谢等生理过程,并调控多种疾病如歌舞伎综合征、癌症等疾病的发生发展。该文对UTX的最新研究成果进行总结,并就其在疾病治疗中的可能作用展开讨论。     

Dephosphorylation-induced EZH2 activation mediated RECK downregulation by ERK1/2 signaling

The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) gene, a widely known cancer inhibitor, could effectively suppress cancer metastasis and angiogenesis. Downregulation or loss of RECK expression frequently occurs during cancer progression. However, the mechanism underlying RECK dysregulation has not been fully elucidated. Herein, we reported for the first time that enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, could epigenetically attenuate RECK expression via catalyzing H3K27 trimethylation (H3K27me3) within the RECK promoter. Furthermore, we also proved, for the first time, the involvement of EZH2 in the inhibition of RECK by extracellular signal-related kinases (ERK)-1/2 signaling. Next, we revealed that the modulation of the enzymic activity of EZH2 resulting from posttranslational phosphorylation at the serine-21 site was responsible for the increased enrichment of H3K27me3 at the RECK promoter region by ERK1/2 signaling. Collectively, the results of our study shed more light on the mechanisms responsible for the dysregulation of RECK by the ERK1/2 pathway.     

JMJD3 as an epigenetic regulator in development and disease

Gene expression is epigenetically regulated through DNA methylation and covalent chromatin modifications, such as acetylation, phosphorylation, ubiquitination, sumoylation, and methylation of histones. Histone methylation state is dynamically regulated by different groups of histone methyltransferases and demethylases. The trimethylation of histone 3 (H3K4) at lysine 4 is usually associated with the activation of gene expression, whereas trimethylation of histone 3 at lysine 27 (H3K27) is associated with the repression of gene expression. The polycomb repressive complex contains the H3K27 methyltransferase Ezh2 and controls dimethylation and trimethylation of H3K27 (H3K27me2/3). The Jumonji domain containing-3 (Jmjd3, KDM6B) and ubiquitously transcribed X-chromosome tetratricopeptide repeat protein (UTX, KDM6A) have been identified as H3K27 demethylases that catalyze the demethylation of H3K27me2/3. The role and mechanisms of both JMJD3 and UTX have been extensively studied for their involvement in development, cell plasticity, immune system, neurodegenerative disease, and cancer. In this review, we will focus on recent progresses made on understanding JMJD3 in the regulation of gene expression in development and diseases. This article is part of a Directed Issue entitled: Epigenetics dynamics in development and disease.     

A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma

The chromatin modifier EZH2 is overexpressed and associated with inferior outcome in mantle cell lymphoma (MCL). Recently, we demonstrated preferential DNA methylation of HOX genes in MCL compared with chronic lymphocytic leukemia (CLL), despite these genes not being expressed in either entity. Since EZH2 has been shown to regulate HOX gene expression, to gain further insight into its possible role in differential silencing of HOX genes in MCL vs. CLL, we performed detailed epigenetic characterization using representative cell lines and primary samples. We observed significant overexpression of EZH2 in MCL vs. CLL. Chromatin immune precipitation (ChIP) assays revealed that EZH2 catalyzed repressive H3 lysine 27 trimethylation (H3K27me3), which was sufficient to silence HOX genes in CLL, whereas in MCL H3K27me3 is accompanied by DNA methylation for a more stable repression. More importantly, hypermethylation of the HOX genes in MCL resulted from EZH2 overexpression and subsequent recruitment of the DNA methylation machinery onto HOX gene promoters. The importance of EZH2 upregulation in this process was further underscored by siRNA transfection and EZH2 inhibitor experiments. Altogether, these observations implicate EZH2 in the long-term silencing of HOX genes in MCL, and allude to its potential as a therapeutic target with clinical impact.     

ERK signaling is triggered by hepatitis C virus E2 protein through DC-SIGN

Dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) is a binding receptor for hepatitis C virus (HCV). Binding of HCV envelope protein E2 to target cells is a prerequisite to DC-SIGN-mediated signaling. Using cell lines with stable or transient expression of DC-SIGN, we investigated effects of soluble HCV E2 protein on ERK pathway. MEK and ERK are activated by the E2 in NIH3T3 cells stably expressing DC-SIGN. Treatment of the cells with antibody to DC-SIGN results in inhibition of the E2 binding as well as the E2-induced MEK and ERK activation. In HEK293T cells transiently expressing DC-SIGN, activation of MEK and ERK is also induced by the E2. Activation of ERK pathway by HCV E2 through DC-SIGN provides useful information for understanding cellular receptor-mediated signaling.     

EZH2: an emerging role in melanoma biology and strategies for targeted therapy

Histone modifications are increasingly being recognized as important epigenetic mechanisms that govern chromatin structure and gene expression. EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2), responsible for tri‐methylation of lysine 27 on histone 3 (H3K27me3) that leads to gene silencing. This highly conserved histone methyltransferase is found to be overexpressed in many different types of cancers including melanoma, where it is postulated to abnormally repress tumor suppressor genes. Somatic mutations have been identified in approximately 3% of melanomas, and activating mutations described within the catalytic SET domain of EZH2 confer its oncogenic activity. In the following review, we discuss the evidence that EZH2 is an important driver of melanoma progression and we summarize the progress of EZH2 inhibitors against this promising therapeutic target.